Portfolio company
Modulus Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops engineered NK-cell therapies for autoimmune disease patients using a generative design and rapid prototyping platform.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Modulari-T Biosciences
This company develops modular immune receptors and delivery vehicles to create cell and gene therapies for patients with cancer and autoimmune diseases.
Artiva Biotherapeutics
The company develops allogeneic natural killer cell therapies for patients with autoimmune diseases and cancer.
Nkarta
This biopharmaceutical company develops engineered natural killer cell therapies to treat patients with cancer and autoimmune diseases.
Graph Therapeutics
This company develops artificial intelligence technology to create targeted therapies and biomarkers for patients with immune-mediated diseases.
Candid Therapeutics
This clinical-stage biotechnology company develops T-cell engager antibodies for patients with autoimmune and inflammatory diseases.
Mozart Therapeutics
The company develops CD8 T regulatory cell modulators to treat patients with autoimmune and inflammatory diseases including type 1 diabetes.
Autolus Therapeutics
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.
Rhapsogen
This biotechnology company develops precision biologic therapeutics to treat autoimmune diseases by modulating antibody effector functions for patients with inflammatory conditions.